Physician profile
Susan E Harold
NPI 1093780611
$14,405.43
in general payments reported to CMS, 2019-2025
38 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,080 · 2020: $1,232 · 2021: $1,400 · 2022: $2,173 · 2023: $2,246 · 2024: $1,551 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,160 · Education: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,159.94 |
| Education | $360.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,076.66 | 2019-2025 | Opdivo, Onureg, Reblozyl |
| Glaxosmithkline, LLC. | $1,930.81 | 2019-2025 | Arexvy, Trelegy Ellipta, Ojjaara |
| Gilead Sciences, INC. | $1,598.21 | 2019-2023 | Epclusa |
| Alexion Pharmaceuticals, INC. | $1,111.78 | 2019-2023 | |
| Genzyme Corporation | $738.81 | 2020-2025 | |
| Abbvie INC. | $700.03 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $584.92 | 2021-2024 | Libtayo |
| Astellas Pharma US INC | $559.69 | 2022-2025 | Padcev, Xtandi |
| Eisai INC. | $511.14 | 2019-2025 | |
| Genentech USA, INC. | $490.56 | 2019 | |
| Janssen Biotech, INC. | $375.73 | 2019-2023 | Erleada |
| Pfizer INC. | $342.40 | 2019-2023 | |
| Sobi, INC | $318.54 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $255.58 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $246.13 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $243.54 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $225.83 | 2019 | |
| Dova Pharmaceuticals | $218.98 | 2019-2021 | |
| Lilly USA, LLC | $153.34 | 2020-2024 | Mounjaro |
| Cti Biopharma Corp. | $130.24 | 2023 | Vonjo |
| Incyte Corporation | $125.00 | 2023 | Monjuvi |
| Janssen Pharmaceuticals, INC | $124.98 | 2019 | |
| Allergan, INC. | $124.74 | 2019 | |
| Intercept Pharmaceuticals, INC. | $124.10 | 2019 | |
| Axsome Therapeutics, INC. | $122.97 | 2024 | Auvelity |
| Novo Nordisk INC | $122.54 | 2019 | |
| Verastem, INC. | $121.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.79 | 2022 | |
| Pharmacosmos Therapeutics INC. | $109.19 | 2022 | |
| Vifor Pharma, INC. | $89.95 | 2019 | |
| Beigene USA, INC. | $88.58 | 2022 | |
| Aveo Pharmaceuticals, INC. | $84.60 | 2023 | Fotivda |
| Foundation Medicine, INC. | $81.14 | 2019 | |
| Tesaro, INC. | $43.87 | 2019 | |
| Celgene Corporation | $38.02 | 2021-2023 | Reblozyl |
| Azurity Pharmaceuticals, INC. | $35.05 | 2025 | Danziten |
| Esperion Therapeutics, INC. | $21.90 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Harold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.